Arecor Therapeutics Statistics
Total Valuation
Arecor Therapeutics has a market cap or net worth of GBP 29.26 million. The enterprise value is 22.85 million.
Market Cap | 29.26M |
Enterprise Value | 22.85M |
Important Dates
The next estimated earnings date is Monday, September 23, 2024.
Earnings Date | Sep 23, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Arecor Therapeutics has 37.76 million shares outstanding. The number of shares has increased by 5.83% in one year.
Shares Outstanding | 37.76M |
Shares Change (YoY) | +5.83% |
Shares Change (QoQ) | +0.02% |
Owned by Insiders (%) | 7.95% |
Owned by Institutions (%) | 37.79% |
Float | 25.20M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5.19 |
PB Ratio | 2.49 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.67 |
EV / Sales | 5.00 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -3.81 |
Financial Position
The company has a current ratio of 2.17, with a Debt / Equity ratio of 3.55.
Current Ratio | 2.17 |
Quick Ratio | 1.96 |
Debt / Equity | 3.55 |
Debt / EBITDA | n/a |
Debt / FCF | -0.06 |
Interest Coverage | -611.67 |
Financial Efficiency
Return on equity (ROE) is -63.41% and return on invested capital (ROIC) is -41.54%.
Return on Equity (ROE) | -63.41% |
Return on Assets (ROA) | -30.88% |
Return on Capital (ROIC) | -41.54% |
Revenue Per Employee | 91,460 |
Profits Per Employee | -171,080 |
Employee Count | 50 |
Asset Turnover | 0.25 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.33% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -57.33% |
50-Day Moving Average | 93.97 |
200-Day Moving Average | 137.57 |
Relative Strength Index (RSI) | 28.11 |
Average Volume (20 Days) | 8,331 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Arecor Therapeutics had revenue of GBP 4.57 million and -8.55 million in losses. Loss per share was -0.28.
Revenue | 4.57M |
Gross Profit | 4.57M |
Operating Income | -9.18M |
Pretax Income | -8.90M |
Net Income | -8.55M |
EBITDA | -8.88M |
EBIT | -9.18M |
Loss Per Share | -0.28 |
Balance Sheet
The company has 6.75 million in cash and 338,000 in debt, giving a net cash position of 6.41 million or 0.17 per share.
Cash & Cash Equivalents | 6.75M |
Total Debt | 338,000 |
Net Cash | 6.41M |
Net Cash Per Share | 0.17 |
Equity (Book Value) | 9.53M |
Book Value Per Share | 0.31 |
Working Capital | 6.02M |
Cash Flow
In the last 12 months, operating cash flow was -5.84 million and capital expenditures -151,000, giving a free cash flow of -5.99 million.
Operating Cash Flow | -5.84M |
Capital Expenditures | -151,000 |
Free Cash Flow | -5.99M |
FCF Per Share | -0.16 |
Margins
Gross margin is 100.00%, with operating and profit margins of -200.63% and -187.05%.
Gross Margin | 100.00% |
Operating Margin | -200.63% |
Pretax Margin | -194.64% |
Profit Margin | -187.05% |
EBITDA Margin | -194.18% |
EBIT Margin | -200.63% |
FCF Margin | -131.03% |
Dividends & Yields
Arecor Therapeutics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -5.83% |
Shareholder Yield | -5.83% |
Earnings Yield | -36.04% |
FCF Yield | -20.48% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |